Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that the U.S. Food and Drug Administ...
– Expansion of solid tumor clinical program – ASPEN-02 dose optimization data to inform dosing for ASPEN-05 SOUTH SAN FRANCISCO, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clin...
SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, Pre...
ALX Oncology press release (NASDAQ:ALXO): Q1 GAAP EPS of -$0.60 beats by $0.11. Cash, cash equivalents and investments as of March 31, 2022 were $341.7 million. ALX Oncology believes its cash, cash equivalents and investments are sufficient to fund planned operations through mid-2024. For f...
SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the first quarte...
SOUTH SAN FRANCISCO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the appointment of Itziar Canamasas...
ALX Oncology Holdings Inc. (NASDAQ:ALXO) traded today at a new 52-week high of $117.45. Approximately 4.1 million shares have changed hands today, as compared to an average 30-day volume of 362,000 shares. ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on h...
Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) traded at a new 52-week high today of $117.45. Approximately 4.1 million shares have changed hands today, as compared to an average 30-day volume of 397,000 shares. In the past 52 weeks, shares of ALX Oncology Holdings Inc. have traded b...
ALX Oncology Holdings (NASDAQ:ALXO) has filed for a $450M mixed shelf offering. The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company will indicate how it will use the proceeds in a prospectus supplement. The offering can include common ...
ALX Oncology (NASDAQ:ALXO) said the first patient was dosed in a phase 2/3 ASPEN-06 trial evaluating its drug evorpacept and Eli Lilly's (NYSE:LLY) Cyramza (ramucirumab), added to trastuzumab and paclitaxel to treat patients with HER2-positive gastric cancer or gastroesophagea...
News, Short Squeeze, Breakout and More Instantly...
ALX Oncology Holdings Inc. Company Name:
ALXO Stock Symbol:
NASDAQ Market:
ALX Oncology Holdings Inc. Website:
2024-07-09 15:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Evorpacept in combination with PADCEV ® , an approved antibody-drug conjugate (“ADC”), demonstrated promising activity and was generally well tolerated Company to host conference call and webcast with Samuel A. Funt, M.D., of Memorial Sloan Kettering Cancer Center on ...
SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that management wi...